天津医药 ›› 2016, Vol. 44 ›› Issue (4): 501-504.doi: 10.11958/58421

• 药物临床观察 • 上一篇    下一篇

参附注射液联合低剂量氢化可的松对脓毒症多脏器功能障碍综合征患者血浆PCT 和HLA-DR 水平的影响

刘阳, 樊蕴辉, 刘晨△, 解宝泉, 韩晓庆   

  1. 华北理工大学附属医院 (邮编063000)
  • 收稿日期:2015-02-10 修回日期:2015-11-22 出版日期:2016-04-15 发布日期:2016-05-20
  • 通讯作者: 刘晨 E-mail:zyning789@126.com
  • 作者简介:刘阳 (1973), 男, 副主任医师, 主要从事急危重症方面的研究
  • 基金资助:
    河北省医学科学研究重点课题 (20140500)

Effects of Shenfu injection combined with low-dose hydrocortisone on plasma levels of HLA-DR and PCT in patients with septic multiple organ dysfunction syndrome

LIU Yang, FAN Yunhui, LIU Chen△, XIE Baoquan, HAN Xiaoqing   

  1. Affiliated Hospital of North China University of Science and Technology, Tangshan 063000, China
  • Received:2015-02-10 Revised:2015-11-22 Published:2016-04-15 Online:2016-05-20

摘要: 摘要: 目的 观察参附注射液联合低剂量氢化可的松对脓毒症多脏器功能障碍综合征患者血浆降钙素原 (PCT)和单核细胞表面人类白细胞抗原 DR 位点 (HLA-DR) 水平的影响。方法 将 118 例脓毒症多脏器功能障碍综合征患者按随机数字表法分为对照组 (39 例)、 观察 1 组 (39 例) 和观察 2 组 (40 例)。对照组行常规治疗, 观察 1 组在常规综合治疗基础上应用参附注射液 100 mL, 2 次/d, 共 7 d; 观察 2 组在观察 1 组基础上应用低剂量氢化可的松 200 mg/d, 静脉注射, 连用 14 d。分别于入院当天、 治疗后 1 d、 3 d 和 7 d 采集患者清晨空腹静脉血 5 mL, 检测 PCT、 HLA- DR 和过氧化脂质 (LPO) 水平。并记录治疗 14 d 内患者的死亡情况。结果 治疗 14 d 内, 对照组、 观察 1 组和观察 2 组病死率[分别是 61.5% (24/39)、 41.0% (16/39) 和 25.0% (10/40) ]依次降低 (χ2 =8.150, P<0.05)。治疗前和治疗后 1 d 时 3 组患者血浆 PCT、 HLA-DR 和 LPO 水平差异均无统计学意义; 治疗后 3 d 和 7 d 时, 对照组、 观察 1 组和观察 2 组血浆 PCT、 LPO 水平均依次降低, HLA-DR 水平依次升高 (均 P<0.05)。结论 参附注射液联合低剂量氢化可的松可有效降低 PCT 水平, 提高HLA-DR 水平, 促进脓毒症多脏器功能障碍综合征患者的转归。

关键词: 脓毒症, 多器官功能衰竭, 参附注射液, 氢化可的松, 多脏器功能障碍综合征, 降钙素原, 单核细胞表面, 人类白细胞抗原 DR 位点

Abstract: Abstract: Objective To explore the effects of Shenfu injection combined with low-dose hydrocortisone on plasma lev⁃ els of human leukocyte antigen (HLA)-DR and procalcitonin (PCT) in patients with septic multiple organ dysfunction syn⁃ drome. Methods A total of 118 patients with septic multiple organ dysfunction syndrome were divided into three groups: control group (n=39), experimental group 1 (n=39) and experimental group 2 (n=40). The control group received conventioanl medicine therapy, while the experimental group 1 received Shenfu injection (100 mL, 2 /d, for 7 d) combined with conventio⁃ anl medicine therapy, and the experimental group 2 received Shenfu injection combined with low-dose hydrocortisone (200 mg/d, for 14 d) besides conventional medicine therapy. The peripheral blood samples were collected for the detection of HLA-DR, PCT and lipoperoxide (LPO) before treatment, 1 d, 3 d amd 7 d after treatment. The mortality in 14 d was record⁃ ed. Results The mortality rates in 14 d were 61.5% (24/39), 41.0% (16/39) and 25.0% (10/40) for control group, experimen⁃ tal group 1 and experimental group 2 (χ2 =8.15, P<0.05). There were no significant differences in PCT, HLA-DR and LPO levels before treatment and 1 d after treatment between the three groups (P>0.05). The plasma levels of PCT and LPO were significantly decreased in control group, experimental group 1 and experimental group 2 after 3-d and 7-d treatment, but the levels of HLA- DR was significantly increased (P < 0.05). Conclusion The combination therapy of Shenfu injection and low-dose hydrocortisone can effectively reduce PCT level and increase HLA-DR level, which promotes the improve⁃ ment of patients with septic multiple organ dysfunction syndrome.

Key words: sepsis, multiple organ failure, Shenfu injection, hydrocortisone, multiple organ dysfunction syndromes, PCT , HLA-DR